Because ShK toxins function as potassium-channel blockers, they have been proposed as human pharmaceutical targets to treat obesity (Upadhyay et al. 2013), graft rejection, and autoimmune diseases (Kalman et al. 1998). The gene discussed is KCNA3; the disease is obesity due to melanocortin 4 receptor deficiency.